Dr. Reddy's Reports $135M Profit in Fiscal Q3, Revenue Hits $971M (RDY)

Dr. Reddy's Laboratories Ltd. (RDY) posted a net profit of $135 million in its fiscal third quarter ended December 2025, with per-share earnings of 16 cents. The Hyderabad-based pharmaceutical company reported revenue of $971 million for the period. The results reflect steady performance amid ongoing competitive and regulatory pressures in key markets. The company maintained profitability through cost optimization and increased sales in its generics portfolio. Emerging markets contributed to top-line growth, partially offsetting pricing challenges in North America and Europe. No major corporate actions or guidance updates were announced alongside the earnings.